{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:49:19Z","timestamp":1756993759801,"version":"3.41.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 70-year-old man presented with combined hepatocellular-cholangiocarcinoma underwent partial hepatectomy and chemoradiotherapy approximately 3 months ago. Follow-up abdominal ultrasound detected a new small lesion with decreased echogenicity in the hepatic segment I, potentially indicating recurrence. The patient was enrolled in a clinical trial of comparison of <jats:sup>18<\/jats:sup>F-FDG and <jats:sup>18<\/jats:sup>F-FAPI PET\/CT in hepatic lesions. Compared with non\u2013<jats:sup>18<\/jats:sup>F-FDG avidity, <jats:sup>18<\/jats:sup>F-FAPI PET\/CT showed intense tracer uptake of the hepatic lesion. Resection of the lesion was subsequently performed, and pathologic analysis confirmed the diagnosis of recurrent combined hepatocellular-cholangiocarcinoma.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005148","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T23:00:25Z","timestamp":1712185225000},"page":"e351-e353","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Intense 18F-FAPI Uptake in Small Recurrent Lesions of Combined Hepatocellular-Cholangiocarcinoma Negative on 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"49","author":[{"given":"Jiucen","family":"Liang","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Song","sequence":"additional","affiliation":[{"name":"Pathology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rusen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2021.01.035","article-title":"Combined hepatocellular-cholangiocarcinoma: an update","volume":"74","year":"2021","journal-title":"J Hepatol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.14309\/ajg.0000000000000326","article-title":"Combined hepatocellular cholangiocarcinoma: a population-based retrospective study","volume":"114","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00259-019-04327-2","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with combined hepatocellular-cholangiocarcinoma","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40644-023-00626-y","article-title":"Head-to-head comparison of 18F-FAPI and 18F-FDG PET\/CT in staging and therapeutic management of hepatocellular carcinoma","volume":"23","year":"2023","journal-title":"Cancer Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","article-title":"Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","article-title":"[18F]FAPI PET\/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/RLU.0000000000003863","article-title":"Hepatic lesion of mucosa-associated lymphoid tissue lymphoma revealed by Al18F-NOTA-FAPI-04 PET\/CT","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/RLU.0000000000004073","article-title":"Tumor imaging with 68Ga-DOTA-FAPI-04 PET\/CT: comparison with 18F-FDG PET\/CT in 22 different cancer types","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/RLU.0000000000004374","article-title":"Superiority of 68Ga-FAPI-04 in delineation of soft tissue and liver metastases in chromophobe renal cell carcinoma for restaging","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1097\/RLU.0000000000004924","article-title":"Multiple intrahepatic inflammatory myofibroblastic tumor on 68Ga-FAPI and 18F-FDG PET\/CT","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/RLU.0000000000004909","article-title":"Comparison of 18F-FDG and 68Ga-FAPI PET\/CT in a patient with hepatic perivascular epithelioid cell neoplasm","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1097\/RLU.0000000000003015","article-title":"68Ga-FAPI PET\/CT in assessment of liver nodules in a cirrhotic patient","volume":"45","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:01:39Z","timestamp":1750532499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005148","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}